New BiTE-EV therapy tested for Tough-to-Treat leukemia
NCT ID NCT06890494
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called BiTE-EV for adults with relapsed or hard-to-treat B-cell leukemia. The main goals are to see if it is safe and if it can help control the disease. Only 3 participants will take the therapy every other day for 1-2 months and then have regular checkups. This is a very small safety study, so results will be preliminary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer could sharpen diagnosis of blood cancers
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- New dashboard aims to make leukemia trials more inclusive
- Gene mapping of childhood blood cancers could unlock personalized treatments
- Could an ALS drug clear the fog of chemo brain?
- Triple therapy aims to overcome antibody barrier in Half-Matched stem cell transplants